drugset / Trial / NCT07284277
TTFields and Chemotherapy in Metastatic Pancreatic Adenocarcinoma (mPDAC)
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this clinical trial is to assess the safety and tolerability of TTFields in combination with chemotherapy in adults with metastatic pancreatic adenocarcinoma based on treatment-emergent adverse events of chemotherapy (modFOLFIRINOX) or device (TTFields). The main questions it aims to answer are: * Is TTFields treatment safe for the patients in combination with modFOLFIRINOX? * Are participants compliant with the treatment? * Is Is TTFields treatment effective in combination with modFOLFIRINOX against metastatic pancreatic adenocarcinoma?
Timeline
- Start
- 2025-10-14
- Primary completion
- 2027-03
- Completion
- 2027-03
Publications
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Background | Irinotecan | Small molecule | 150 mg/m2 | — |
| Background | Irinotecan | Small molecule | 180 mg/m2 | — |
| Background | Oxaliplatin | Small molecule | 85 mg/m2 | — |
| Background | fluorouracil | Small molecule | 2400 mg/m2 | — |
| Background | folic acid | Other / unclassified | 200 mg/m2 | — |
| Background | folic acid | Other / unclassified | 400 mg/m2 | — |